2018
DOI: 10.1111/bjd.16820
|View full text |Cite
|
Sign up to set email alerts
|

Improvements in quality of life and work productivity make omalizumab cost-effective for the treatment of chronic spontaneous urticaria

Abstract: Linked Article: Kanters et al. Br J Dermatol 2018; 179:702–708.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
0
0

Publication Types

Select...

Relationship

0
0

Authors

Journals

citations
Cited by 0 publications
references
References 10 publications
0
0
0
Order By: Relevance

No citations

Set email alert for when this publication receives citations?